Ivermectin Fails to Statistically Beat Placebo in Colombian Study & Mass Media Finally Takes Notice—An Interesting Observation

Ivermectin Fails to Statistically Beat Placebo in Columbian Study & Mass Media Finally Takes Notice—An Interesting Observation

Recently, the results of a new ivermectin study out of Columbia were reported in the medical journal JAMA. Led by Eduardo Lopez Medina, MD, a physician and researcher at the Center for Pediatric infectious Diseases in Cali, Colombia, the double-blind, placebo controlled randomized clinical trial was organized to test the efficacy of ivermectin in preventing progression of disease in adult patients with early states of COVID-19. Interestingly, as the results were not compelling, the New York Times decided to swoop in on the news. The study (Lopez 2021) team found the patient participants taking the 5-day course of ivermectin failed to significantly improve the time to resolution of the symptoms. Although the investigative team concluded that the study results failed to support the use of ivermectin as a treatment of mild COVID-19, they acknowledge that perhaps larger trials may be needed to better understand the effects of the drug on other clinically relevant outcomes. TrialSite suggests that the results of this study do little to change the comprehensive meta analyses currently generated from researchers in America and the UK.

The study results indicated the time to resolution...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee